DROSHA
Ribonuclease 3
Also known as: Etohi2, HSA242976, RN3, RNASE3L, RNASEN, RNC_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9NRR4
- Gene
- DROSHA
- Ensembl
- ENSG00000113360
- Chromosome
- 5
- Canonical length
- 1374 aa
- Protein class
- Cancer-related genes, Enzymes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
This gene encodes a ribonuclease (RNase) III double-stranded RNA-specific ribonuclease and subunit of the microprocessor protein complex, which catalyzes the initial processing step of microRNA (miRNA) synthesis. The encoded protein cleaves the stem loop structure from the primary microRNA (pri-miRNA) in the nucleus, yielding the precursor miRNA (pre-miRNA), which is then exported to the cytoplasm for further processing. In a human cell line lacking a functional copy of this gene, canonical miRNA synthesis is reduced. Somatic mutations in this gene have been observed in human patients with kidney cancer. [provided by RefSeq, Sep 2016]
Canonical amino-acid sequenceUniProt
1374 residues, UniProt reviewed canonical sequence.
>Q9NRR4|DROSHA
1 MMQGNTCHRM SFHPGRGCPR GRGGHGARPS APSFRPQNLR LLHPQQPPVQ YQYEPPSAPS
61 TTFSNSPAPN FLPPRPDFVP FPPPMPPSAQ GPLPPCPIRP PFPNHQMRHP FPVPPCFPPM
121 PPPMPCPNNP PVPGAPPGQG TFPFMMPPPS MPHPPPPPVM PQQVNYQYPP GYSHHNFPPP
181 SFNSFQNNPS SFLPSANNSS SPHFRHLPPY PLPKAPSERR SPERLKHYDD HRHRDHSHGR
241 GERHRSLDRR ERGRSPDRRR QDSRYRSDYD RGRTPSRHRS YERSRERERE RHRHRDNRRS
301 PSLERSYKKE YKRSGRSYGL SVVPEPAGCT PELPGEIIKN TDSWAPPLEI VNHRSPSREK
361 KRARWEEEKD RWSDNQSSGK DKNYTSIKEK EPEETMPDKN EEEEEELLKP VWIRCTHSEN
421 YYSSDPMDQV GDSTVVGTSR LRDLYDKFEE ELGSRQEKAK AARPPWEPPK TKLDEDLESS
481 SESECESDED STCSSSSDSE VFDVIAEIKR KKAHPDRLHD ELWYNDPGQM NDGPLCKCSA
541 KARRTGIRHS IYPGEEAIKP CRPMTNNAGR LFHYRITVSP PTNFLTDRPT VIEYDDHEYI
601 FEGFSMFAHA PLTNIPLCKV IRFNIDYTIH FIEEMMPENF CVKGLELFSL FLFRDILELY
661 DWNLKGPLFE DSPPCCPRFH FMPRFVRFLP DGGKEVLSMH QILLYLLRCS KALVPEEEIA
721 NMLQWEELEW QKYAEECKGM IVTNPGTKPS SVRIDQLDRE QFNPDVITFP IIVHFGIRPA
781 QLSYAGDPQY QKLWKSYVKL RHLLANSPKV KQTDKQKLAQ REEALQKIRQ KNTMRREVTV
841 ELSSQGFWKT GIRSDVCQHA MMLPVLTHHI RYHQCLMHLD KLIGYTFQDR CLLQLAMTHP
901 SHHLNFGMNP DHARNSLSNC GIRQPKYGDR KVHHMHMRKK GINTLINIMS RLGQDDPTPS
961 RINHNERLEF LGDAVVEFLT SVHLYYLFPS LEEGGLATYR TAIVQNQHLA MLAKKLELDR
1021 FMLYAHGPDL CRESDLRHAM ANCFEALIGA VYLEGSLEEA KQLFGRLLFN DPDLREVWLN
1081 YPLHPLQLQE PNTDRQLIET SPVLQKLTEF EEAIGVIFTH VRLLARAFTL RTVGFNHLTL
1141 GHNQRMEFLG DSIMQLVATE YLFIHFPDHH EGHLTLLRSS LVNNRTQAKV AEELGMQEYA
1201 ITNDKTKRPV ALRTKTLADL LESFIAALYI DKDLEYVHTF MNVCFFPRLK EFILNQDWND
1261 PKSQLQQCCL TLRTEGKEPD IPLYKTLQTV GPSHARTYTV AVYFKGERIG CGKGPSIQQA
1321 EMGAAMDALE KYNFPQMAHQ KRFIERKYRQ ELKEMRWERE HQEREPDETE DIKKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against DROSHA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.4
- Highest tissue expression
- 25 nTPM
Expression across tissuesHPA
Tissue
- retina: 25 nTPM
- thymus: 23 nTPM
- skeletal muscle: 21 nTPM
- epididymis: 19 nTPM
- tongue: 18 nTPM
- ovary: 18 nTPM
Single-cell type
- oligodendrocyte progenitor cells: 101 nCPM
- lactotrophs: 93 nCPM
- gonadotrophs: 88 nCPM
- pituitary stem cells: 88 nCPM
- pituicytes/fscs: 85 nCPM
- adrenal medulla cells: 85 nCPM
Immune cell
- plasmacytoid DC: 3 nTPM
- memory CD8 T-cell: 2.7 nTPM
- naive CD4 T-cell: 2.7 nTPM
- myeloid DC: 2.5 nTPM
- NK-cell: 2.5 nTPM
- non-classical monocyte: 2.5 nTPM
Brain region
- cerebral cortex: 68 nTPM
- cerebellum: 57 nTPM
- hypothalamus: 55 nTPM
- thalamus: 48 nTPM
- white matter: 48 nTPM
- choroid plexus: 47 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about DROSHA.
Disease | GeneticClinVar
9 pathogenic / likely-pathogenic of 261 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.35
- gnomAD pLI
- 0.09
- gnomAD missense Z
- 3.98
- DepMap mean gene effect
- -0.56
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 15% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- defense response to Gram-negative bacterium
- defense response to Gram-positive bacterium
- miRNA metabolic process
- positive regulation of gene expression
- pre-miRNA processing
- primary miRNA processing
- regulation of inflammatory response
- regulation of miRNA metabolic process
- regulation of regulatory T cell differentiation
- rRNA processing
Molecular functions
- DEAD/H-box RNA helicase binding
- lipopolysaccharide binding
- metal ion binding
- primary miRNA binding
- protein homodimerization activity
- R-SMAD binding
- ribonuclease III activity
- RNA binding
- SMAD binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Ribonuclease III domain
- Double-stranded RNA-binding domain
- Ribonuclease III, endonuclease domain superfamily
- Double-stranded RNA binding motif
- Ribonuclease III domain
- Ribonuclease III
- RNase III, double-stranded RNA binding domain, animal
- Ribonuclease 3, central domain, two antiparallel helical region
- Ribonuclease-III-like
- Ribonuclease 3, central domain, two antiparallel helical region
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of DROSHA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DROSHA as an antibody target. Whether an autoantibody or antibody against DROSHA could matter depends on whether native DROSHA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DROSHA is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label DROSHA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...